Insider Buying: GSK (LON:GSK) Insider Buys £52,850 in Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 2,500 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The stock was purchased at an average price of GBX 2,114 per share, for a total transaction of £52,850.

Jonathan Symonds also recently made the following trade(s):

• On Monday, December 22nd, Jonathan Symonds purchased 1,650 shares of GSK stock. The shares were purchased at an average price of GBX 1,810 per share, with a total value of £29,865.

GSK Trading Up 0.8%

Shares of LON:GSK opened at GBX 2,198 on Monday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock’s 50-day moving average is GBX 1,846.14 and its 200-day moving average is GBX 1,670.90. The company has a market cap of £88.68 billion, a P/E ratio of 16.53, a P/E/G ratio of 1.24 and a beta of 0.31. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,066.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK Chair Sir Jonathan Symonds purchased 2,500 shares at GBX 2,114 (≈£52,850), signaling insider confidence. GSK Chair Sir Jonathan Symonds Buys Additional Shares in the Company
• Positive Sentiment: EU approved GSK’s Nucala for use in uncontrolled COPD — expands label and addressable market for an existing respiratory franchise. EU gives GSK’s Nucala green light for use in uncontrolled COPD
• Positive Sentiment: EU granted adult approval for GSK’s RSV vaccine — a major commercial milestone that supports revenue growth expectations for respiratory vaccines. GSK RSV Vaccine Wins EU Adult Approval As Shares Trade Above Targets
• Positive Sentiment: Brokerage action: Shore Capital reaffirmed a “buy” rating and GBX 2,300 target — provides independent support for upside vs. current levels. Broker Ratings
• Positive Sentiment: Q4 results beat: GSK reported stronger-than-expected Q4 profit and highlighted strategic execution — this underpins near-term earnings momentum. GSK PLC Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Market commentary/valuation pieces note a ~47% one-year share gain and debate whether the stock remains attractively valued — useful context for investors weighing further upside vs. valuation risk. Is GSK Still Attractive After A 47% One-Year Share Price Gain
• Negative Sentiment: Guidance caution: Management flagged a likely slowdown in sales growth for 2026 under the new CEO — raises near-term growth concerns and tempers the upbeat reaction to approvals and the quarter. GSK sees slower sales growth in 2026

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Berenberg Bank upped their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Citigroup reiterated a “buy” rating and issued a GBX 1,900 target price on shares of GSK in a research note on Tuesday, January 27th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Finally, Shore Capital Group reaffirmed a “buy” rating and issued a GBX 2,300 price target on shares of GSK in a report on Wednesday, February 4th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of GBX 1,867.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.